242 related articles for article (PubMed ID: 22776860)
1. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
McClung MR; Lewiecki EM; Geller ML; Bolognese MA; Peacock M; Weinstein RL; Ding B; Rockabrand E; Wagman RB; Miller PD
Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
[TBL] [Abstract][Full Text] [Related]
2. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
3. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
[TBL] [Abstract][Full Text] [Related]
8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
9. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
10. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
11. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
12. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Miller PD; Bolognese MA; Lewiecki EM; McClung MR; Ding B; Austin M; Liu Y; San Martin J
Bone; 2008 Aug; 43(2):222-229. PubMed ID: 18539106
[TBL] [Abstract][Full Text] [Related]
13. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
14. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
18. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
19. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
